Fabrizio Minervini, Savvas Lampridis, Peter Kestenholz, Esther Pardo, Julie Crommelinck, Paul Martin Putora, Marlène Schnider, Matteo Petroncini, Nora Mayer, Pietro Bertoglio
{"title":"吸烟对肺癌患者的影响。","authors":"Fabrizio Minervini, Savvas Lampridis, Peter Kestenholz, Esther Pardo, Julie Crommelinck, Paul Martin Putora, Marlène Schnider, Matteo Petroncini, Nora Mayer, Pietro Bertoglio","doi":"10.1183/16000617.0175-2024","DOIUrl":null,"url":null,"abstract":"<p><p>Although smoking prevalence has shown a decreasing trend, the total number of smokers remains high due to population growth. Smoking causes several diseases, including lung cancer, COPD, coronary heart disease, stroke and peripheral vascular disease. Most of the adverse effects of smoking are reversible and smoking cessation treatments are a cost-effective and high-impact intervention for reducing the risk of mortality and morbidity from smoking-related illness. Smoking cessation may have a significant impact in patients diagnosed with lung cancer, as continued tobacco use can critically compromise treatment efficacy, increase the risk of recurrence and reduce overall survival. Moreover, the benefits of smoking cessation in lung cancer patients can also improve quality of life. The tremendous health and economic consequences of the smoking epidemic should make tobacco control a top priority for governments worldwide. This review aims to highlight the necessity of incorporating smoking cessation as a standard component of lung cancer treatment protocols to enhance patients' clinical outcomes and quality of life. At the same time, we identified a lack of current evidence regarding the optimal timing of smoking cessation among lung cancer patients, which provides the basis for further investigation.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"34 176","pages":""},"PeriodicalIF":9.0000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220743/pdf/","citationCount":"0","resultStr":"{\"title\":\"The impact of smoking on lung cancer patients.\",\"authors\":\"Fabrizio Minervini, Savvas Lampridis, Peter Kestenholz, Esther Pardo, Julie Crommelinck, Paul Martin Putora, Marlène Schnider, Matteo Petroncini, Nora Mayer, Pietro Bertoglio\",\"doi\":\"10.1183/16000617.0175-2024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Although smoking prevalence has shown a decreasing trend, the total number of smokers remains high due to population growth. Smoking causes several diseases, including lung cancer, COPD, coronary heart disease, stroke and peripheral vascular disease. Most of the adverse effects of smoking are reversible and smoking cessation treatments are a cost-effective and high-impact intervention for reducing the risk of mortality and morbidity from smoking-related illness. Smoking cessation may have a significant impact in patients diagnosed with lung cancer, as continued tobacco use can critically compromise treatment efficacy, increase the risk of recurrence and reduce overall survival. Moreover, the benefits of smoking cessation in lung cancer patients can also improve quality of life. The tremendous health and economic consequences of the smoking epidemic should make tobacco control a top priority for governments worldwide. This review aims to highlight the necessity of incorporating smoking cessation as a standard component of lung cancer treatment protocols to enhance patients' clinical outcomes and quality of life. At the same time, we identified a lack of current evidence regarding the optimal timing of smoking cessation among lung cancer patients, which provides the basis for further investigation.</p>\",\"PeriodicalId\":12166,\"journal\":{\"name\":\"European Respiratory Review\",\"volume\":\"34 176\",\"pages\":\"\"},\"PeriodicalIF\":9.0000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220743/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Respiratory Review\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1183/16000617.0175-2024\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Respiratory Review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/16000617.0175-2024","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"Print","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Although smoking prevalence has shown a decreasing trend, the total number of smokers remains high due to population growth. Smoking causes several diseases, including lung cancer, COPD, coronary heart disease, stroke and peripheral vascular disease. Most of the adverse effects of smoking are reversible and smoking cessation treatments are a cost-effective and high-impact intervention for reducing the risk of mortality and morbidity from smoking-related illness. Smoking cessation may have a significant impact in patients diagnosed with lung cancer, as continued tobacco use can critically compromise treatment efficacy, increase the risk of recurrence and reduce overall survival. Moreover, the benefits of smoking cessation in lung cancer patients can also improve quality of life. The tremendous health and economic consequences of the smoking epidemic should make tobacco control a top priority for governments worldwide. This review aims to highlight the necessity of incorporating smoking cessation as a standard component of lung cancer treatment protocols to enhance patients' clinical outcomes and quality of life. At the same time, we identified a lack of current evidence regarding the optimal timing of smoking cessation among lung cancer patients, which provides the basis for further investigation.
期刊介绍:
The European Respiratory Review (ERR) is an open-access journal published by the European Respiratory Society (ERS), serving as a vital resource for respiratory professionals by delivering updates on medicine, science, and surgery in the field. ERR features state-of-the-art review articles, editorials, correspondence, and summaries of recent research findings and studies covering a wide range of topics including COPD, asthma, pulmonary hypertension, interstitial lung disease, lung cancer, tuberculosis, and pulmonary infections. Articles are published continuously and compiled into quarterly issues within a single annual volume.